%0 Journal Article
%T Melanoma-associated antigen A1 and A3 as new candidate of diagnostic for non-small cell lung cancer
%A Isnin Anang Marhana
%A Muhammad Amin
%A Gondo Mastutik
%A Oski Illiandri
%J Journal of Advanced Pharmacy Education and Research
%@ 2249-3379
%D 2021
%V 11
%N 2
%R 10.51847/f4blrw8EhW
%P 1-4
%X The early diagnosis of lung cancer has long been an interesting field for early treatment of the disease. Many diagnostic methods use specific tumor antigens for the diagnosis of lung cancer with low to medium specificity and sensitivity. Recently, melanoma-associated antigen (MAGE) A1 and A3 detection has been emerged as a new tool for lung cancer diagnosis and can be a promising tool in the future. However, it still needs to be investigated to measure the sensitivity and specificity. This research is an analytic observational study conducted at Dr. Soetomo Hospital Surabaya. The population of the study was all patients diagnosed with suspected lung cancer. The research sample was 100 patients’ biopsy samples of lung cancer patients who underwent a core biopsy (CB), bronchoalveolar lavage (BAL), and forceps biopsy (FB) (31 core biopsy, 37 BAL, and 32 forceps biopsy). The sample was taken by histopathology and the expression of MAGE A1 and A2 was measured. The results were analyzed using the Chi-Square Test using SPSS for Mac Version 20.00. Histopathologic results on CB, BAL, and FB showed that 37 patients were positive for carcinoma (47.7%), with the majority of adenocarcinoma (31.6%) and the results of the PA CB, the sensitivity value was 30.43% and the specificity value was 75.00%. In conclusion, the examination of the tumor antigen MAGE A1 and A3 can be used as a new candidate for lung cancer diagnosis in the future‎.
%U https://japer.in/article/melanoma-associated-antigen-a1-and-a3-as-new-candidate-of-diagnostic-for-non-small-cell-lung-cancer-9l0zqnnlzkzreot